Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this retrospective study, researchers found that baricitinib was effective for treating moderate to severe alopecia areata, with response rates in 24 patients comparable to existing real-world data, and no new safety concerns were identified.

This study developed a kidney-specific knockout mouse model lacking the Flcn gene, which recapitulates human Birt-Hogg-Dubé kidney tumorigenesis and shows that mTOR pathway inhibition with rapamycin can suppress tumor growth.

This study found that folliculin deficient renal cancer cells were more sensitive to irradiation due to increased autophagic cell death, suggesting a potentially enhanced therapeutic approach when combined with autophagy inducers like rapamycin.

This review discusses the efficacy, safety, and practical aspects of using Janus kinase inhibitors—baricitinib, ritlecitinib, and deuruxolitinib—as treatments for severe alopecia areata in an advanced practice provider context, without reporting specific study results.

This review highlights that bicalutamide, a non-steroidal antiandrogen used in prostate cancer treatment, is mainly effective through its (R)-enantiomer and emphasizes the need to monitor its adverse effects despite its targeted antiandrogenic action.